Amicus Therapeutics Inc (FOLD) Stock

About Amicus Therapeutics Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease; and DMX-200, a small molecule inhibitor of the chemokine receptor 2 that is in a pivotal Phase 3 study for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold; and Dimerix Limited for the commercialization of DMX-200 for the treatment of FSGS and other indications. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey. As of April 27, 2026, Amicus Therapeutics, Inc. operates as a subsidiary of BioMarin Pharmaceutical Inc.

Amicus Therapeutics Inc (FOLD) stock trades at $14.49 with a market capitalization of $4.55B. The stock is valued at a negative price-to-earnings (P/E) ratio of -161.00, reflecting a net loss over the last twelve months, price-to-book of 16.61, price-to-sales of 7.17. Over the past 52 weeks the stock has ranged between $5.51 and $14.50, and currently trades at or near its 52-week high.

On profitability, Amicus Therapeutics Inc generates a return on equity (ROE) of -9.85% (negative, reflecting a net loss), return on capital employed of 12.41%, an operating margin of 5.36%, a net profit margin of -4.27%.

Amicus Therapeutics Inc by the numbers, 2016–2025

Between 2016 and 2025 Amicus Therapeutics Inc reported revenue of $5.0M rising to $634.0M, a change of +12580.0% across 10 years. Compounded, revenue has grown 19.4% a year over five years, 24.4% over three, 20.1% over the last twelve months. Net profit rose to $-27.0M.

Operating margin went from -3668.6% in 2016 to 5.4% in 2025, a gain of 3674.1 percentage points. The most recent net margin is -4.27%. On a trailing twelve-month basis to Dec '25, revenue is $634.0M and net profit $-27.0M.

Borrowings rose from $154.0M to $483.0M, cash from operations was $33.0M in the latest year, positive in 1 of the last 10.

Return on equity has averaged -81.6% over five years, and was -9.8% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Amicus Therapeutics Inc (FOLD) — frequently asked questions